Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-04
DOI
10.1038/s41409-020-01159-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years
- (2020) Angelo Belotti et al. AMERICAN JOURNAL OF HEMATOLOGY
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial
- (2020) Sandra Maria Dold et al. HAEMATOLOGICA
- The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma
- (2020) Mark A. Fiala et al. Journal of Geriatric Oncology
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Tolerability of high dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: A single-center retrospective analysis
- (2020) H. Wiebach et al. Current Research in Translational Medicine
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
- (2020) Saad Z Usmani et al. Lancet Haematology
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
- (2020) Pashna N. Munshi et al. CANCER
- Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma
- (2020) Hao Meng Yip et al. Hematology/ Oncology and Stem Cell Therapy
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma
- (2019) Edward A. Stadtmauer et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
- (2019) Gordon Cook et al. Lancet Haematology
- Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents
- (2019) Shohei Mizuno et al. BONE MARROW TRANSPLANTATION
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years
- (2019) Qaiser Bashir et al. LEUKEMIA & LYMPHOMA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
- (2019) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
- (2018) M Hasib Sidiqi et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
- (2018) Carolina Marini et al. ANNALS OF HEMATOLOGY
- Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
- (2018) Guido Ghilardi et al. BONE MARROW TRANSPLANTATION
- Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older
- (2018) Anays Murillo et al. Journal of Geriatric Oncology
- Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
- (2018) Ashley R. Paquin et al. Blood Cancer Journal
- Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma
- (2017) Nina Shah et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
- (2016) Paolo Milani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation
- (2016) Christa E. Nath et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
- (2014) H W Auner et al. BONE MARROW TRANSPLANTATION
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents
- (2013) M. Merz et al. ANNALS OF ONCOLOGY
- Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry
- (2012) Massimo Offidani et al. Clinical Lymphoma Myeloma & Leukemia
- Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative
- (2009) Morie A. Gertz et al. MAYO CLINIC PROCEEDINGS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started